<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179971</url>
  </required_header>
  <id_info>
    <org_study_id>Charite-n-3-n-6</org_study_id>
    <nct_id>NCT01179971</nct_id>
  </id_info>
  <brief_title>n-3 and n-6 Fatty Acids in Rheumatoid Arthritis</brief_title>
  <official_title>Incorporation of n-3 Long Chain Polyunsaturated Fatty Acids and Gamma Linolenic Acid in Plasma Lipids, Cholesteryl Esters, and Erythrocyte Membranes and Their Influence on Disease Activity in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To investigate into the differential effects of polyunsaturated fatty acids as
      compared to standard control therapy (olive oil) on disease activity and biochemical
      parameters in patients with rheumatoid arthritis (RA), resp. psoriasis arthritis (PA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: Double-blinded, four-armed randomised controlled trial with 3.0 g/d of either n-3
      long chain polyunsaturated fatty acids (LC-PUFA) or gamma linolenic acid (GLA), resp. the
      combination of 1.5 g/d of each, resp. 3.0 g/d of olive oil over 12 weeks. Outcome parameters
      disease activity score (DAS28), C-reactive protein, concentrations of n-3 LC-PUFA, resp. GLA
      in plasma lipids (PL), cholesterol esters (CE), and erythrocyte membranes (EM), and serum
      concentrations of arachidonic acid (AA). Conventional antirheumatic and immunosuppressive
      therapies could be changed only within defined limits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incorporation of eicosapentaenoic acid in plasma lipids</measure>
    <time_frame>12 weeks</time_frame>
    <description>ratio of arachidonic acid/eicosapentaenoic acid in plasma lipids</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease activity score 28 (DAS28, EULAR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Disease activity as determinated by counts of swollen and tender joints, patient's judgement and erythrocyte sedimentation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>12 weeks</time_frame>
    <description>most common marker of acute systemic inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Normalized Ratio (INR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>most common single marker for crude quantification of hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>12 weeks</time_frame>
    <description>registration of complaints for taste, odor, or mechanical properties of the supplements</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3g/d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gamma-linolenic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3g/d gamma-linolenic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil plus GLA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 g/d DHA + EPA plus 1.5g/d gamma-linolenic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olive oil</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>3 g/d olive oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil, gamma-linolenic acid</intervention_name>
    <description>3 g/d DHA + EPA</description>
    <arm_group_label>Fish oil</arm_group_label>
    <arm_group_label>Gamma-linolenic Acid</arm_group_label>
    <arm_group_label>Fish oil plus GLA</arm_group_label>
    <arm_group_label>Olive oil</arm_group_label>
    <other_name>Fish oil, omega-6 fatty acids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid or Psoriasis arthritis

        Exclusion Criteria:

          -  Severe diseases of heart, liver, lung airways

          -  Non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Stange, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Immanuel Krankenhaus and Charite Berlin</affiliation>
  </overall_official>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>August 25, 2010</last_update_submitted>
  <last_update_submitted_qc>August 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Rainer Stange, M.D. Ph.D.</name_title>
    <organization>Abteilung für Naturheilkunde Charité</organization>
  </responsible_party>
  <keyword>n-3 fatty acids</keyword>
  <keyword>n-6 fatty acids</keyword>
  <keyword>anti-inflammatory action</keyword>
  <keyword>clinical trial</keyword>
  <keyword>randomized double-blinded</keyword>
  <keyword>incorporation of fatty acids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efamol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

